Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).

Ridolfi L, de Rosa F, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Riccobon A, Gentili G, Nanni O, Framarini M, Tauceri F, Guidoboni M.

BMJ Open. 2018 Aug 5;8(8):e021701. doi: 10.1136/bmjopen-2018-021701.

2.

Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone.

Bulgarelli J, Fiammenghi L, Cassan S, Granato AM, Petrini M, Pancisi E, Soldati V, De Rosa F, Ridolfi L, Riccobon A, Guidoboni M.

Cytotherapy. 2018 Jun;20(6):851-860. doi: 10.1016/j.jcyt.2018.04.002. Epub 2018 May 10.

3.

Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.

de Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Framarini M, Tauceri F, Migliori G, Brolli C, Gentili G, Petracci E, Nanni O, Riccobon A, Ridolfi R, Guidoboni M.

Melanoma Res. 2017 Aug;27(4):351-357. doi: 10.1097/CMR.0000000000000356.

PMID:
28654547
4.

Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.

de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M.

J Transl Med. 2014 Jul 22;12:209. doi: 10.1186/1479-5876-12-209.

5.

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.

Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, de Rosa F, Valmorri L, Scarpi E, Nicoletti SV, Baravelli S, Riccobon A, Ridolfi R.

J Transl Med. 2013 May 31;11:135. doi: 10.1186/1479-5876-11-135.

6.

Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.

Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R.

Melanoma Res. 2011 Dec;21(6):524-9. doi: 10.1097/CMR.0b013e32834b58fa.

PMID:
21909041
7.

Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis.

Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Scarpi E, Guidoboni M, Migliori G, Sanna S, Tauceri F, Verdecchia GM, Riccobon A, Valmorri L, Ridolfi R.

Clin Dev Immunol. 2010;2010:504979. doi: 10.1155/2010/504979. Epub 2010 Sep 27. Erratum in: Clin Dev Immunol. 2011;2011:283896. Valmorri, Linda [added].

8.

FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy.

Fiammenghi L, Ancarani V, Rosales T, Knutson JR, Petrini M, Granato AM, Pancisi E, Ridolfi L, Ridolfi R, Riccobon A, Neyroz P.

J Transl Med. 2010 Jun 3;8:52. doi: 10.1186/1479-5876-8-52.

9.

Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome.

Venanzi FM, Petrini M, Fiammenghi L, Bolli E, Granato AM, Ridolfi L, Gabrielli F, Barucca A, Concetti A, Ridolfi R, Riccobon A.

Cancer Immunol Immunother. 2010 Jan;59(1):27-34. doi: 10.1007/s00262-009-0717-4. Epub 2009 May 7.

PMID:
19440709
10.

Human embryo immune escape mechanisms rediscovered by the tumor.

Ridolfi L, Petrini M, Fiammenghi L, Riccobon A, Ridolfi R.

Immunobiology. 2009;214(1):61-76. doi: 10.1016/j.imbio.2008.03.003. Epub 2008 Jun 17. Review.

PMID:
19159828
11.

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients.

Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini M, Migliori G, Riccobon A.

J Transl Med. 2006 Aug 16;4:36.

12.

Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes.

Riccobon A, Gunelli R, Ridolfi R, De Paola F, Flamini E, Fiori M, Saltutti C, Petrini M, Fiammenghi L, Stefanelli M, Granato AM, Cuzzocrea DE, Amadori D.

Cancer Invest. 2004;22(6):871-7.

PMID:
15641485
13.

Evaluation of in vivo labelled dendritic cell migration in cancer patients.

Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Moretti A, Migliori G, Fiorentini G.

J Transl Med. 2004 Jul 30;2(1):27.

14.

Dendritic cell vaccination and immunostimulation in advanced melanoma.

Ridolfi R, Ridolfi L, Petrini M, Fiammenghi L, Riccobon A.

Expert Rev Vaccines. 2003 Dec;2(6):825-33. Review.

PMID:
14711365
15.

Chemotherapy and bio-chemotherapy in patients with advanced melanoma: combination therapy with a nitrosourea.

Ridolfi R, Tanganelli L, Scelzi E, Manente P, Palmeri S, Ravaioli A, Fiammenghi L, Romanini A; Italian Melaoma Intergroup.

J Chemother. 2003 Apr;15(2):198-202.

PMID:
12797399

Supplemental Content

Loading ...
Support Center